Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

54.87USD
23 Feb 2018
Change (% chg)

$0.30 (+0.55%)
Prev Close
$54.57
Open
$54.82
Day's High
$55.00
Day's Low
$54.57
Volume
2,934,245
Avg. Vol
3,997,885
52-wk High
$66.80
52-wk Low
$53.36

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $149,489.80
Shares Outstanding(Mil.): 2,724.44
Dividend: 0.48
Yield (%): 3.50

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

Merck to buy virus-based cancer drug firm Viralytics for $394 million

U.S. drugmaker Merck & Co , already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its pipeline in the sector.

Feb 21 2018

UPDATE 2-Merck to buy virus-based cancer drug firm Viralytics for $394 mln

* "Tuck-in" deal broadens Merck's immuno-oncology line-up (Adds analyst comment, more on virus science)

Feb 21 2018

Merck to buy Viralytics for $394 mln to boost immuno-oncology

Feb 21 U.S. drugmaker Merck & Co, already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its drug pipeline.

Feb 21 2018

BRIEF-Merck And Viralytics Announce Acquisition Agreement

* MERCK AND VIRALYTICS ANNOUNCE ACQUISITION AGREEMENT, EXPANDING MERCK'S LEADING IMMUNO-ONCOLOGY PIPELINE

Feb 21 2018

Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

Feb 17 2018

UPDATE 1-Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

Feb 17 2018

Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

Feb 17 2018

BRIEF-Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1

* SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR NEUROFIBROMATOSIS TYPE 1

Feb 15 2018

BRIEF-Nestle declines to comment on interest in Pfizer, Merck units

* CEO SAYS NO COMMENT ON INTEREST IN PFIZER, MERCK CONSUMER HEALTH UNITS, BUT IS GENERALLY INTERESTED IN EXPANDING ITS CONSUMER HEALTH BUSINESS

Feb 15 2018

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Feb 14 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $132.02 +2.11
Pfizer Inc. (PFE.N) $36.26 +0.52
AbbVie Inc (ABBV.N) $118.75 +1.19
Eli Lilly and Co (LLY.N) $78.75 +1.56
Bristol-Myers Squibb Co (BMY.N) $67.95 +2.01
Bristol-Myers Squibb Co (BMYMP.PK) $1,306.55 +216.55

Earnings vs. Estimates